Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03962725 · ClinicalTrials.gov registry record · Phase 4
Avoiding Neuromuscular Blockers to Reduce Complications
A Phase 4 study, sponsored by Beth Israel Deaconess Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT03962725: Clinical Trial Phase 4 study, sponsored by Beth Israel Deaconess Medical Center.
NCT03962725 is a Phase 4 study that was terminated before completion, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 3 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03962725, a Phase 4 study, was terminated before completion, sponsored by Beth Israel Deaconess Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
The goal of this study to evaluate whether eliminating the use of non-depolarizing neuromuscular blocking agents (NMBA) for maintenance of general anesthesia reduces postoperative pulmonary complications in higher risk patients.
Primary Outcome
Composite of respiratory failure, suspected respiratory infection, aspiration pneumonia or pneumonitis, atelectasis, bronchospasm, reintubation and all cause in-hospital mortality
Interventions
- DRUG Neuromuscular Blocking Agents
- DRUG Anesthetic Adjuncts
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-08-07 |
| Est. Completion | 2022-12-19 |
| Phase | Phase 4 |
Why NCT03962725 stopped before completion
NCT03962725 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Neuromuscular Blocking Agents is the first listed.
NCT03962725 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03962725 about?
NCT03962725 is a clinical study titled "Avoiding Neuromuscular Blockers to Reduce Complications". The goal of this study to evaluate whether eliminating the use of non-depolarizing neuromuscular blocking agents (NMBA) for maintenance of general anesthesia reduces postoperative pulmonary complications in higher risk patients.
What is the current status of trial NCT03962725?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2019-08-07. Estimated completion is 2022-12-19.
What interventions are being tested in trial NCT03962725?
The interventions under investigation include: Neuromuscular Blocking Agents (DRUG), Anesthetic Adjuncts (DRUG).
Who is sponsoring clinical trial NCT03962725?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03962725's enrollment target sits among peer trials
3 1995th of 2000 higher than 3 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI